Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. (Q48587395)

13 February 2018

title

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. (English)

1 reference

13 February 2018

0 references

3

Oldfield EH

1 reference

13 February 2018

author name string

Laske DW

series ordinal

1

1 reference

13 February 2018

Youle RJ

series ordinal

2

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 December 1997

1 reference

13 February 2018

published in

Nature Medicine

1 reference

13 February 2018

volume

3

1 reference

13 February 2018

page(s)

1362-1368

1 reference

13 February 2018

issue

12

1 reference

13 February 2018

https://scigraph.springernature.com/pub.10.1038/nm1297-1362

exact match

0 references

cites work

Epidemiology of brain tumors: the national survey of intracranial neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

National survey of patterns of care for brain-tumor patients

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Modulation of cell surface iron transferrin receptors by cellular density and state of activation

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Transferrin and transferrin receptors in carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Transferrin receptors in human tissues: their distribution and possible clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Transferrin receptor on endothelium of brain capillaries

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

The distribution of transferrin immunoreactivity in the rat central nervous system.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Intracerebral chemotherapy: chronic microinfusion of cisplatin.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Convection-enhanced delivery of macromolecules in the brain

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

https://api.crossref.org/works/10.1038%2FNM1297-1362

1 reference

7 January 2021

Redesigning nature's poisons to create anti-tumor reagents

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1362

7 January 2021

Identifiers

DOI

10.1038/NM1297-1362

1 reference

13 February 2018

PubMed ID

9396606

1 reference

13 February 2018